ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PTGX / dividends
TGTX (63) MDGL (38) CORT (63) CYTK (28) ⌘ Pro Terminal →

Protagonist Therapeutics Inc. (PTGX) Dividend Safety Gauge & 10-Year DRIP Compounder

$144.85 +0.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $144.67

Protagonist Therapeutics Inc. (PTGX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $9.37B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PTGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PTGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Protagonist Therapeutics Inc. (NASDAQ: PTGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $144.85 (+0.35% 1D, market cap $9.37B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, PTGX ranks #115 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PTGX compare to TGTX and MDGL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTGX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -16.7%. By comparison, TGTX (TG Therapeutics Inc.) holds a C grade (63/100 RQD, P/E 19.9x, ROIC 12.0%, cap $9.36B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PTGX?
▼

Per PTGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001377121), Protagonist Therapeutics Inc. generated $442.8M in revenue (-37.5% YoY), -$130.1M in net income, and $56.1M in free cash flow against $668.2M in total assets and $24.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $144.66 (-0.13%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 12.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510065
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B-
Cash (13)Whales (16)SEC (14)Macro (14)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE+3.1% Base Target
$176 Bull$149 Base$117 Bear
📬 FREE PTGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTGX)Realized 20D OHLCV Swing Band: ±7.9%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY PTGX SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±7.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$136.28+1.3% Next Q
Q2 (-2Q)
60
Grade C$138.08+2.9% Next Q
Q3 (-1Q)
62
Grade C+$142.14+1.9% Next Q
Current
65
Grade C$144.85+1.3% Hist 90D α
Trajectory: C (57) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PTGX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, PTGX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($142.41) or 200D SMA ($117.54) invalidates the momentum regime and cuts Target Base ($149.41) toward Bear Floor ($116.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PTGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in PTGX & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on PTGX and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PTGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +45.55%⚡ TESTING RESISTANCE
2026-11-03O $144.3H $144.9L $144.3C $144.9VOL 322.6K
RES: $148.2SUP: $125.4SMA50: $142.4SMA200: $117.5
$166.5$143.0$119.6$96.14$72.69RES $148.2SUP $125.4$144.92026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTGX Butterfly Map → + Track PTGX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
23.9%/yr Implied 5Y Growth

vs. -37.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PTGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PTGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTGX)

Health Care Rank #115 of 1015 ⚔️ TGTX vs PTGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTGX vs. TGTX, MDGL, CORT, CYTK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Protagonist Therapeutics Inc. (PTGX) ranks #115 by composite RQD confidence (65/100, grade C) and #117 by equity capitalization ($9.37B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PTGX ACTIVE
Protagonist Therapeutics Inc.
C 65/100 — — -16.7% +0.35% $9.37B Benchmark Subject
TGTX
TG Therapeutics Inc.
C 63/100 19.9x 83.7% 12.0% +5.34% $9.36B /tgtx-vs-ptgx →
MDGL
Madrigal Pharmaceuticals Inc.
D- 38/100 — — -29.7% -0.31% $9.94B /mdgl-vs-ptgx →
CORT
Corcept Therapeutics Incorporated
C 63/100 93.2x 96.0% 4.8% -5.62% $8.77B /cort-vs-ptgx →
CYTK
Cytokinetics Incorporated
E 28/100 — — -35.0% -0.50% $8.76B /cytk-vs-ptgx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001377121 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Protagonist Therapeutics Inc. (PTGX) reported GAAP revenue of $442.8M (-37.5% vs. FY2024 revenue of $708.0M , and +68.8% cumulative change since FY2023) , GAAP net income of -$130.1M, operating cash flow of $57.7M, and free cash flow of $56.1M (-69.3% YoY). On the balance sheet, PTGX closed FY2025 with $668.2M in total assets against $24.1M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $442.8M -$130.1M $57.7M $56.1M $668.2M $24.1M
FY2024 (FY) 2024-12-31 $708.0M $275.2M $184.2M $182.8M $744.7M $31.2M
FY2023 (FY) 2023-12-31 $262.2M -$79.0M -$70.2M -$70.2M $5.14B $1.20B

3. PTGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Protagonist Therapeutics Inc. (NASDAQ: PTGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $144.85 (+0.35% 1D, market cap $9.37B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, PTGX ranks #115 in composite RQD confidence.

How does PTGX compare to TGTX and MDGL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTGX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -16.7%. By comparison, TGTX (TG Therapeutics Inc.) holds a C grade (63/100 RQD, P/E 19.9x, ROIC 12.0%, cap $9.36B) and MDGL (Madrigal Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -29.7%, cap $9.94B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PTGX?

Per PTGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001377121), Protagonist Therapeutics Inc. generated $442.8M in revenue (-37.5% YoY), -$130.1M in net income, and $56.1M in free cash flow against $668.2M in total assets and $24.1M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PTGX trading relative to its 50-day, 200-day, and 52-week technical levels?

PTGX last traded at $144.85 (+0.35% on volume of 322,629 shares), positioning the stock +1.71% above its 50-day simple moving average ($142.41) and +23.23% above its 200-day simple moving average ($117.54). Across its 52-week range of $75.44 to $160.81, PTGX sits at the 81.3% percentile with a 14-day RSI of 57.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.9% ($133.41 to $156.29).

Direct Sub-Reports: PTGX RQD Cockpit PTGX 12M Forecast PTGX Earnings & Move PTGX Dividends & DRIP PTGX Insiders & 13F PTGX Whale Options PTGX Profit Sankey PTGX News & Why
ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

PTGX — Protagonist Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Protagonist Therapeutics Inc. (PTGX) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $144.85 (+0.35% 1D, market capitalization $9.37B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -16.7%, gross margin of —, operating margin of -6.0%, and free cash flow yield of 0.60%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (14/20): Incorporates a 0.99x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 6/9, and Debt/Equity of 0.04x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Protagonist Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — across all listed periods so the source does not establish how the company generates income.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Protagonist Therapeutics Inc. (PTGX) reported $442.8M in annual revenue (up from $708.0M in FY2024, -37.5% YoY) and -$130.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($262.2M revenue, -$79.0M net income) through FY2025, PTGX scaled operating cash flow to $57.7M and free cash flow to $56.1M, backed by $668.2M in total assets against $24.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 65/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 0.60% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $75.44 – $160.81 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -6.0% operating margins and a 0.99x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PTGX carries a macro regime beta of 0.99 and gross margin of —.

  • Key Question #1: Can PTGX sustain or expand its -6.0% operating margin and -16.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $442.8M and free cash flow of $56.1M, how will capital allocation balance growth reinvestment against $24.1M in total debt?
  • Key Question #3: How sensitive is PTGX's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?

PTGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Protagonist Therapeutics Inc. (PTGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PTGX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PTGX Bull vs. Bear Conversation Board — What's Your Call at $144.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PTGX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PTGX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $173.82 (+20.0%)
📌 Pinned Debate

Balance sheet strength (Altman Z 26, Debt/Equity 0.04) and institutional accumulation support the stock despite negative returns.

Long PTGX at $144.85 targeting $173.82. Balance sheet strength (Altman Z 26, Debt/Equity 0.04) and institutional accumulation support the stock despite negative returns.. Institutional whale score is 16/20 and the risk/reward vs. the $75.44 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@FadeTheHype Shorting a 16/20 institutional whale-flow stock at $144.85 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $121.67 (-16.0%)
Spot @ $144.85

Negative ROIC of -16.7%, FY 2025 net loss of -$130.1M, and a forward P/E of 31 against negative trailing EPS leave the valuation depend

Here is the bear case nobody on the bull side wants to address on PTGX: Negative ROIC of -16.7%, FY 2025 net loss of -$130.1M, and a forward P/E of 31 against negative trailing EPS leave the valuation dependent on unproven earnings.. At 31.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%